dotMD.com
Join Community
📖Formal Study Breakdown Talk in Gut, Labs & Supplements Space 711+ Logs • Free →🧮Lab Calculator ↓
Reading this clinical breakthrough? See how real patients are applying these numbers in real life. Compare real-world patient outcomes, lab numbers, and doctor visit tips—100% free with a private @handle and zero login wall.
Click to Ask a Question or Post Your Experience ▾
Post to Gut, Labs & Supplements Space (15 Seconds • No Account or Email Required)
Or read existing discussions in Gut, Labs & Supplements Space →
Back to Plain-English 8th-Grade Story
Google Scholar NIH PubMed #42586114
Official NIH NLM MEDLINE / PubMed Citation • PMID: 42586114

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.

Lancet

Verbatim Formal Study Abstract

Between March 5, 2021, and Sept 1, 2023, 955 individuals were screened for eligibility, 747 of whom were randomly assigned to belzutifan-lenvatinib (n=371) or cabozantinib (n=376).